lifestyle.californiaconsumerbanking.com

Author: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

May 4, 2026
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

May 3, 2026
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

May 3, 2026
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

May 3, 2026
Apogee Therapeutics to Participate in Upcoming March Conferences

April 28, 2026
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

April 26, 2026
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

April 1, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing

March 30, 2026
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

March 30, 2026
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

March 30, 2026